Clinical Trials Using PI3K Delta/Gamma Inhibitor RP6530
Clinical trials are research studies that involve people. The clinical trials on this list are studying PI3K Delta/Gamma Inhibitor RP6530. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed / Refractory T-cell Lymphoma
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R / R T-cell lymphoma.
Location: 7 locations
Compassionate Use Study of Tenalisib (RP6530)
Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed / refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed / refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies.
Location: See Clinical Trials.gov